218 related articles for article (PubMed ID: 18359327)
1. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease.
Mansencal N; Mitry E; Pillière R; Lepère C; Gérardin B; Petit J; Gandjbakhch I; Rougier P; Dubourg O
Am J Cardiol; 2008 Apr; 101(7):1035-8. PubMed ID: 18359327
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
[TBL] [Abstract][Full Text] [Related]
3. Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
Vigna C; Inchingolo V; Giannatempo G; Pacilli MA; Di Viesti P; Fusilli S; Amico CM; Santoro T; Lanna P; Fanelli R; Simone P; Loperfido F
Am J Cardiol; 2008 Apr; 101(7):1051-5. PubMed ID: 18359330
[TBL] [Abstract][Full Text] [Related]
4. Patent foramen ovale in carcinoid heart disease.
Mansencal N; Touhami I; Mitry E; Rougier P; Dubourg O
Int J Cardiol; 2010 Jul; 142(2):e29-31. PubMed ID: 19157592
[TBL] [Abstract][Full Text] [Related]
5. Urgent transcatheter closure of patent foramen ovale followed by elective right-sided valve surgery for decompensated carcinoid heart disease.
Hayashi Y; McGaw DJ; Goldstein J
Heart Lung Circ; 2008 Jun; 17(3):259-61. PubMed ID: 17416551
[TBL] [Abstract][Full Text] [Related]
6. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
[TBL] [Abstract][Full Text] [Related]
8. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
[TBL] [Abstract][Full Text] [Related]
9. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
[TBL] [Abstract][Full Text] [Related]
11. New onset atrial fibrillation after patent foramen ovale closure.
Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
[TBL] [Abstract][Full Text] [Related]
12. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale.
Rodés-Cabau J; Mineau S; Marrero A; Houde C; Mackey A; Côté JM; Chetaille P; Delisle G; Bertrand OF; Rivest D
Am J Cardiol; 2008 Mar; 101(5):688-92. PubMed ID: 18308022
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage.
Papa M; Gaspardone A; Fragasso G; Ajello S; Gioffrè G; Iamele M; Iani C; Margonato A
Am J Cardiol; 2009 Aug; 104(3):434-9. PubMed ID: 19616680
[TBL] [Abstract][Full Text] [Related]
15. Comparison of contemporary devices used for transcatheter patent foramen ovale closure.
Spies C; Reissmann U; Timmermanns I; Schräder R
J Invasive Cardiol; 2008 Sep; 20(9):442-7. PubMed ID: 18762672
[TBL] [Abstract][Full Text] [Related]
16. Closure of persistent foramen ovale with the BioSTAR biodegradable PFO closure device: feasibility and long-term outcome.
Karagianni A; Abrahamsson P; Furenäs E; Eriksson P; Dellborg M
Scand Cardiovasc J; 2011 Oct; 45(5):267-72. PubMed ID: 21728789
[TBL] [Abstract][Full Text] [Related]
17. Anatomy of the patent foramen ovale for the interventionalist.
McKenzie JA; Edwards WD; Hagler DJ
Catheter Cardiovasc Interv; 2009 May; 73(6):821-6. PubMed ID: 19330826
[TBL] [Abstract][Full Text] [Related]
18. Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies.
Wöhrle J; Kochs M; Spiess J; Nusser T; Hombach V; Merkle N
Circulation; 2009 Jun; 119(23):3002-8. PubMed ID: 19487592
[TBL] [Abstract][Full Text] [Related]
19. [Chronic outcome of percutaneous transcatheter patent foramen ovale closure with Left-disk-coated patent foramen ovale occluder].
Huang YG; Zhang CJ; Huang XS; Huang T; Huang WH
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1132-5. PubMed ID: 20193187
[TBL] [Abstract][Full Text] [Related]
20. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
